Enzo Biochem Inc. (NYSE:ENZ) shot up 9.5% during trading on Friday following a stronger than expected earnings report. The company traded as high as $5.70 and last traded at $5.55, with a volume of 411,025 shares. The stock had previously closed at $5.07.
The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. Enzo Biochem had a negative return on equity of 20.77% and a net margin of 17.27%. The firm earned $26.60 million during the quarter. During the same quarter in the prior year, the firm earned ($0.06) earnings per share.
Separately, Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th.
Hedge funds and other institutional investors have recently modified their holdings of the company. A.R.T. Advisors LLC bought a new position in shares of Enzo Biochem during the second quarter valued at about $101,000. Cubist Systematic Strategies LLC acquired a new position in shares of Enzo Biochem during the second quarter valued at $111,000. BlackRock Advisors LLC increased its position in shares of Enzo Biochem by 148.5% in the second quarter. BlackRock Advisors LLC now owns 19,949 shares of the company’s stock valued at $119,000 after buying an additional 11,921 shares during the period. KBC Group NV increased its position in shares of Enzo Biochem by 207.8% in the second quarter. KBC Group NV now owns 20,551 shares of the company’s stock valued at $123,000 after buying an additional 13,875 shares during the period. Finally, American International Group Inc. increased its position in shares of Enzo Biochem by 2,184.6% in the second quarter. American International Group Inc. now owns 22,846 shares of the company’s stock valued at $136,000 after buying an additional 21,846 shares during the period. Hedge funds and other institutional investors own 53.29% of the company’s stock.
The firm has a market capitalization of $258.40 million, a P/E ratio of 14.6215 and a beta of 1.50. The firm’s 50-day moving average is $5.34 and its 200 day moving average is $5.68.
Enzo Biochem Company Profile
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.